Lichen Sclerosus as a Shared Immune Terrain Marker
Lichen sclerosus (LS) is a chronic inflammatory dermatosis classified as a Th1-dominant autoimmune condition. Its cytokine signature — elevated IL-7, IL-15, IFN-γ, and TNF-α, with reduced IL-10 — overlaps substantially with the immune profile documented in active-phase ME/CFS . Both conditions also show regulatory T cell dysfunction via the miR-155/Foxp3 axis and share genetic risk loci (PTPN22, CTLA4) associated with classical autoimmune diseases (Batham and Smith 2024). Oxidative stress markers (elevated malondialdehyde and 8-hydroxydeoxyguanosine, reduced superoxide dismutase) are independently documented in both .
Large population studies confirm that LS clusters with other autoimmune conditions: thyroiditis, alopecia areata, vitiligo, Sjögren syndrome, and systemic lupus erythematosus are among the most elevated comorbidities (Kassels et al. 2024) (Gulin et al. 2023). ME/CFS shows a similar comorbidity phenotype — its autoimmune overlap includes Hashimoto thyroiditis, Sjögren syndrome, and SLE (Batham and Smith 2024). This shared comorbidity landscape suggests a common immune predisposition terrain rather than coincidental co-occurrence.
Critically, no published study has directly measured LS prevalence in ME/CFS populations or vice versa. The question of whether LS co-occurs in ME/CFS at rates exceeding population background is entirely open. The null result from the closest available proxy — fibromyalgia — is informative but not decisive: Halonen et al. (n = 10,692) found no significant association between fibromyalgia and LS (OR 0.85, 95% CI 0.61–1.18) (Halonen et al. 2024). Since fibromyalgia and ME/CFS overlap substantially but are not equivalent, this result constrains but does not close the question.
Certainty: 0.25. Based on shared Th1 cytokine profiles, overlapping Treg dysfunction, shared genetic risk loci, and a parallel autoimmune comorbidity landscape between LS and ME/CFS. No direct epidemiological evidence exists; certainty reflects mechanistic inference only. Not replicated.
Both lichen sclerosus and ME/CFS fail to fulfil classical autoimmune disease criteria despite clear immune dysregulation signatures. Both are associated with the same cluster of autoimmune conditions (Hashimoto’s, Sjögren’s, SLE, vitiligo), suggesting they may arise from a shared underlying immune predisposition — a terrain of chronic Th1 over-activation and Treg insufficiency that can manifest in different target organs depending on genetic, hormonal, and local tissue factors. In this model, LS is not a consequence of ME/CFS but a parallel manifestation of the same dysregulated immune terrain: the skin and mucosa expressing what ME/CFS expresses systemically.
Mechanistic pathway: Persistent Th1 overactivation → clonal antigen-driven T cell selection in tissue → local cytokine loop (IL-7/IL-15 sustain effector T cells; IFN-γ drives stromal fibrosis via TGF-β) → irreversible fibrosis once established. ECM1 dysfunction (extracellular matrix protein 1, autoantibodies present in 75% of vulvar LS cases) amplifies the loop by impairing basement membrane integrity and releasing neoantigens .
Implication for ME/CFS patients: LS presenting in a patient with unexplained fatigue and post-exertional malaise may represent a diagnostic signal for underlying systemic immune dysregulation rather than an isolated dermatological condition. This does not establish ME/CFS as a cause of LS; it suggests both may reflect a shared immune predisposition that warrants systematic evaluation.
Falsifiable prediction: ME/CFS cohorts prospectively screened for LS will show LS prevalence exceeding age- and sex-matched population controls (expected LS population prevalence: 0.1–3%); conversely, LS cohorts screened for ME/CFS criteria (with PEM assessment) will show ME/CFS prevalence exceeding controls.
Limitations: Entirely speculative; no cohort data. The fibromyalgia-LS null result (Halonen 2024) suggests caution. LS associates selectively with cutaneous/mucosal autoimmunity — RA, T1DM, and MS are null or protective in LS studies, indicating that not all autoimmune terrain produces LS risk (Halonen et al. 2024). Sex and hormonal factors (LS is far more common in post-menopausal women) may confound any ME/CFS-LS prevalence comparison without careful stratification.
If LS and ME/CFS share immune predisposition terrain, the temporal question becomes clinically relevant: does LS onset typically precede, follow, or coincide with ME/CFS onset? A prodromal pattern — LS appearing months to years before ME/CFS criteria are met — would support a shared terrain model where cutaneous immune dysregulation is an early systemic signal. A concurrent pattern would suggest parallel manifestations. A post-ME/CFS pattern could indicate ME/CFS-driven systemic immune dysfunction enabling secondary mucosal autoimmunity.
Retrospective patient registries (You+ME, UK ME/CFS Biobank) could resolve this with a targeted questionnaire addition (LS diagnosis date relative to ME/CFS onset), at negligible cost.
2 miR-155/Foxp3 Axis as a Shared Epigenetic Switch
Certainty: 0.30. Based on LS miR-155 mechanistic evidence and ME/CFS miRNA EV cargo data from independent studies; direct comparative measurement is absent. Not yet replicated in the ME/CFS context.
LS lesions show consistently elevated miR-155 driving Foxp3 transcript destabilization and regulatory T cell dysfunction . Foxp3 instability removes the brake on Th1 effector responses, perpetuating the IL-7/IL-15/IFN-γ cytokine loop. In ME/CFS, extracellular vesicle miRNA profiling has identified miR-155 family changes in independent cohorts (Wang et al. 2025), suggesting a shared epigenetic switch at the Treg/Th1 balance point. If validated, the miR-155/Foxp3 axis would explain the convergence of both conditions on the same autoimmune comorbidity cluster (Hashimoto’s, Sjögren’s, SLE, vitiligo) while predicting that epigenetic Treg restoration strategies — rather than cytokine-level blockade — would be the durable therapeutic approach.
Falsifiable prediction: Plasma EV miR-155 will be elevated >1.5× in ME/CFS vs healthy controls; elevation will correlate inversely with circulating Foxp3+ Treg frequency (r < −0.35). In an LS+ME/CFS subgroup, miR-155 will be highest.
Limitations: ME/CFS miRNA studies are small and use heterogeneous methods. EV miR-155 elevation is not specific to ME/CFS — it is elevated in many inflammatory states. The causal chain (miR-155 → Foxp3 instability → ME/CFS phenotype) is inferred; direct Treg manipulation experiments in ME/CFS cells are absent.
3 Tissue-Resident Memory T Cells: ME/CFS as Multi-Organ TRM Hyperinflammation
Certainty: 0.30. Supported by LS TRM biology, ME/CFS muscle CD8+ infiltrate data, and the IL-15 trans-presentation convergence; no dedicated TRM density study in ME/CFS tissues exists. Not yet replicated.
LS lesions are dominated by CD8+ tissue-resident memory T cells (TRM; CD103+CD69+) that persist locally through IL-15 trans-presentation and re-activate upon epithelial stress . The same TRM biology has emerged in post-viral syndromes generally. A unifying hypothesis for ME/CFS: the initial infectious trigger seeds multi-organ TRM deposits (gut mucosa, skeletal muscle, dorsal root ganglia, brain parenchyma) that persist indefinitely via IL-15; each subsequent metabolic demand — physical exertion, cognitive load, immune challenge — triggers local TRM reactivation with focal IFN-γ/TNF-α release, producing PEM without detectable systemic inflammation in bulk blood. This framework directly resolves the compartmentalized immunity paradox (Section The Paradox of Invisible Immunity): the pathology is in tissue, blood-based studies miss it.
Implication for PEM: PEM onset delay (symptoms peak 12–24h post-exertion) would correspond to TRM reactivation kinetics — slower than immediate cytokine responses, matching clinical observation. Recovery time (days to weeks) reflects the contraction phase of locally reactivated TRM.
Falsifiable prediction: (1) Muscle biopsy after a standardized PEM provocation will show CD103+CD69+ TRM density >2× pre-PEM baseline. (2) Blocking IL-15 will reduce PEM frequency in a small controlled trial. (3) CD8+ TRM density in gut biopsy will correlate with PEM severity score.
Limitations: Muscle and gut biopsies post-PEM are ethically demanding and rarely performed; the evidence base rests on Light et al. (2009) CD8+ infiltrate data (limited methodology) and cross-disease inference. TRM persistence without ongoing antigen is possible but less stable than antigen-supported TRM; if antigen is absent, TRM would be expected to contract over years — inconsistent with decades-long ME/CFS in some patients unless sustained IL-15 replaces antigenic stimulus. Not yet directly tested in ME/CFS.
4 ECM1-Axis Dysfunction as a Connective-Tissue-Immune Bridge
Certainty: 0.40. Based on ECM1’s documented role in LS pathogenesis, its expression in multiple ME/CFS-relevant tissues (gut basement membrane, vascular endothelium, CNS pericytes), and convergent ME/CFS evidence for gut barrier disruption and BBB fragility. No direct ECM1 measurement in ME/CFS exists. Not yet replicated.
ECM1 (extracellular matrix protein 1) regulates basement membrane integrity by binding perlecan and laminin, and modulates angiogenesis and immune cell trafficking across tissue barriers. In LS, anti-ECM1 autoantibodies (present in ~75% of vulvar cases) unmask neoantigens at the dermoepithelial junction and sustain a self-amplifying inflammatory loop . ECM1 is also expressed in vascular endothelium, gut basement membrane, and CNS pericytes (Human Protein Atlas). If a subset of ME/CFS patients develops anti-ECM1 antibodies or functional ECM1 deficiency — either through autoimmune generation or secondary to chronic Th1-driven basement membrane stress — the consequences would span multiple ME/CFS-relevant compartments simultaneously: increased gut permeability (facilitating LPS translocation and systemic immune activation), impaired BBB integrity (enabling neuroinflammation), and abnormal vascular wall compliance (contributing to orthostatic intolerance).
This would make ECM1 dysfunction a unifying connective-tissue-immune bridge, potentially explaining why ME/CFS patients with LS (or with ECM1 autoantibodies without overt LS) show clustering of gut, neurological, and autonomic symptoms — not as independent comorbidities but as manifestations of a single barrier-integrity deficit.
Falsifiable prediction: Anti-ECM1 antibodies will be detectable at >2× population baseline prevalence (expected ~2–5%) in an unselected ME/CFS cohort (n ≥ 200). Seropositive patients will show elevated zonulin (gut permeability marker) and higher S100B variability (BBB stress marker) compared to seronegative ME/CFS controls, independent of disease duration or severity.
Limitations: ECM1 autoantibody ELISA is standardized for LS diagnosis but has not been applied to ME/CFS cohorts. Whether ECM1 dysfunction in ME/CFS would produce overt LS phenotype or a subclinical barrier-fragility syndrome is unknown. The multicompartment prediction (gut + BBB + vascular simultaneously) is mechanistically plausible but would require highly specific ECM1 loss to produce; local ECM1 isoform variation may limit systemic effects. ECM1 knockout mice (Hamada 2003 — lipoid proteinosis phenotype) suggest severe loss produces dramatic phenotype, but partial loss/autoantibody-mediated dysfunction may have subtler effects.
Certainty: 0.45. Chronic low-grade inflammation (TNF-\(\alpha\), IL-1\(\beta\)) primes the extracellular matrix for degradation in ME/CFS by altering fibroblast function, increasing MMP production, and reducing repair capacity. This “priming” explains disproportionate tissue damage from minor triggers in ME/CFS. (Wirth 2026)
Mechanism. In established fibroblast biology, pro-inflammatory cytokines reprogram fibroblasts toward a catabolic phenotype: TNF-\(\alpha\) and IL-1\(\beta\) upregulate MMP-3 and MMP-9 production while downregulating tissue inhibitors of metalloproteinases (TIMPs). They also reduce collagen and elastin synthesis, impair ECM repair, and increase fibroblast sensitivity to mechanical stress. ME/CFS is characterized by chronic low-grade inflammation with elevated TNF-\(\alpha\) and IL-1\(\beta\) in a subset of patients (Chapter Immune System Dysfunction, Section Cytokines and Inflammatory Mediators). This inflammatory milieu chronically “primes” connective tissue for degradation, creating a state where minor triggers that would be harmless in healthy tissue produce substantial damage.
The “disproportionate damage” phenomenon. This priming model explains a clinical observation that challenges conventional connective tissue understanding: ME/CFS patients often experience disproportionate tissue damage from minor events. A hypermobile patient might stretch “too far” during routine activities—well within normal joint range but excessive for their tissue integrity—and experience tendinopathy or ligament injury out of proportion to the mechanical insult. Under the priming model, the inflammatory state has pre-degraded ECM and elevated MMPs, so a minor mechanical challenge exceeds the tissue’s reduced tolerance, producing disproportionate damage.
Cross-reference. This mechanism complements the HIF-1alpha-Mitochondria-ECM Triad (Chapter Energy Metabolism and Mitochondrial Function, Hypothesis HIF-1alpha-Mitochondria-ECM Pathogenic Triad) and ECM1-Axis Dysfunction (Speculation ECM1 Hypofunction as a Unifying Connective-Tissue-Immune Bridge in ME/CFS). Together, these three hypotheses describe overlapping but distinct pathways by which immune dysfunction and metabolic stress converge on connective tissue pathology.
Falsifiable prediction. ME/CFS fibroblasts pre-exposed to TNF-\(\alpha\)/IL-1\(\beta\) (at concentrations matching patient serum levels) will show: (1) exaggerated MMP-3/MMP-9 response to mechanical stretch compared to control fibroblasts; (2) reduced collagen synthesis rates (hydroxyproline incorporation) after cytokine pre-exposure; (3) impaired ECM deposition in 3D culture (reduced matrix density on confocal imaging); (4) these effects will be reversible with cytokine blockade (anti-TNF, anti-IL-1\(\beta\)). In patients, serum TNF-\(\alpha\)/IL-1\(\beta\) levels will correlate with MMP-3/MMP-9 and with hypermobility-related injury frequency.
Limitations. Not all ME/CFS patients show elevated TNF-\(\alpha\)/IL-1\(\beta\); the hypothesis predicts subgroup specificity. Fibroblast heterogeneity across tissue types may produce different priming responses. The inflammatory priming state may be reversible in vitro but may have cumulative in vivo effects (irreversible ECM damage) that limit therapeutic reversal.
Certainty: 0.35. Extracellular matrix degradation releases matrikines—bioactive ECM fragments—into circulation, where they act as damage-associated molecular patterns (DAMPs) and autoantigens that trigger or sustain autoimmunity in ME/CFS. This “ECM leak” hypothesis connects connective tissue degradation to the GPCR autoantibody phenomenon (Section GPCR Autoantibody-Driven Dysfunction). (Wirth 2026)
Mechanism. When collagen, elastin, laminin, or fibronectin are degraded by MMPs or other proteases, bioactive fragments are released. Some of these fragments (e.g., collagen type II peptides, elastin fragments) are established neoantigens that trigger autoantibody production in other diseases (rheumatoid arthritis, systemic sclerosis). In ME/CFS, chronic ECM degradation from mast cell MMP release (Hypothesis Matrix Stiffness-Mast Cell Priming Positive Feedback Cycle), inflammatory priming (Hypothesis Inflammatory Priming of ECM Degradation Susceptibility), or HIF-1alpha-driven MMP upregulation (Chapter Energy Metabolism and Mitochondrial Function) would continuously release ECM fragments into circulation. These fragments could: (1) activate pattern recognition receptors (TLRs, NLRs) on immune cells, sustaining low-grade inflammation; (2) serve as neoantigens for autoantibody generation, explaining the GPCR autoantibodies documented in ME/CFS; (3) form immune complexes that deposit in vascular tissue, contributing to microvascular pathology.
Connection to GPCR autoantibodies. GPCR autoantibodies in ME/CFS target receptors that are embedded in ECM (adhesion receptors, integrin-associated signaling proteins). Autoantibody generation may initially target ECM fragments due to molecular mimicry or bystander activation during chronic ECM degradation, then cross-react with structurally similar GPCR epitopes. This would explain why autoantibodies target specific GPCRs (\(\beta\) 2-adrenergic, muscarinic) rather than being random—they arise from an ECM-directed autoimmune response that cross-reacts with ECM-associated receptors.
Clinical implications. If ECM fragments drive autoimmunity in ME/CFS, then treatments that reduce ECM degradation (MMP inhibitors, mast cell stabilizers, ARBs for basement membrane restoration) should reduce autoantibody titers over time. Conversely, treatments that only remove existing autoantibodies (immunoadsorption, daratumumab) will provide only transient benefit unless the ongoing ECM degradation driving new autoantibody generation is also addressed.
Falsifiable prediction. ME/CFS patients will show: (1) elevated circulating ECM fragments (collagen degradation markers CTX/NTx, elastin fragments, fibronectin fragments) compared to controls; (2) ECM fragment levels correlating with GPCR autoantibody titers; (3) T cells from ME/CFS patients that proliferate in response to ECM fragments (CFSE proliferation assay); (4) treatments that reduce ECM degradation (MMP inhibitors) will show delayed reduction in autoantibody titers compared to treatments that directly remove antibodies (immunoadsorption).
Limitations. This is a novel, speculative connection with no direct ME/CFS data. ECM fragment measurement is not routine; methodology would need development. GPCR autoantibodies may arise through other mechanisms (molecular mimicry with viral proteins). The hypothesis predicts that all ME/CFS patients with autoantibodies have ongoing ECM degradation, which may not be true.
Certainty: 0.35. Moschini et al. established that HIF-1alpha drives tendinopathy through a VEGF-MMP-3 cascade that operates independently of classical VEGF-mediated angiogenesis (Moschini, Mohanan, et al. 2026). ME/CFS may represent a systemic tendinopathy with the same HIF-1alpha-VEGF-MMP-3 cascade operating diffusely across tissues, explaining the overlap between ME/CFS symptoms and connective tissue pathology. (Sahin et al. 2012)
Mechanism. In the Moschini model, HIF-1alpha stabilizes in hypoxic or inflamed tendon tissue, upregulating both VEGF and MMP-3. VEGF does not primarily induce angiogenesis in this context but acts as a survival factor for tenocytes and increases vascular permeability, allowing inflammatory cell infiltration. MMP-3 (stromelysin) degrades tendon ECM, directly weakening tissue structure. Critically, HIF-1alpha-driven MMP-3 upregulation is VEGF-dependent—blocking VEGF signaling reduces MMP-3, indicating a linear cascade. If ME/CFS represents systemic HIF-1alpha elevation (Chapter Energy Metabolism and Mitochondrial Function documents HIF-1alpha in ME/CFS), then the same cascade could operate diffusely in muscle, connective tissue, and vascular adventitia, producing systemic ECM weakening.
Systemic tendinopathy as a disease model. Tendinopathy is characterized by: (1) pain disproportionate to visible damage; (2) failure of normal tissue repair despite abundant fibroblasts; (3) chronic progression with acute exacerbations; (4) minimal response to anti-inflammatories. These features mirror ME/CFS. If ME/CFS is a systemic tendinopathy—HIF-1alpha elevation driving VEGF-MMP-3 across connective tissues—then the tendinopathy literature provides mechanistic insights applicable to ME/CFS. The Moschini finding that VEGF inhibition reduces MMP-3 suggests a therapeutic target: VEGF-neutralizing antibodies (bevacizumab) or VEGF receptor inhibitors might reduce MMP-3-mediated ECM degradation in ME/CFS.
Falsifiable prediction. ME/CFS tissues (muscle biopsy, tendon when clinically indicated) will show: (1) elevated HIF-1alpha, VEGF, and MMP-3 co-localization (immunohistochemistry); (2) MMP-3 expression correlating with both HIF-1alpha and VEGF levels; (3) VEGF receptor expression on fibroblasts and tenocytes; (4) ex vivo VEGF inhibition reducing MMP-3 expression in patient-derived fibroblasts more than in control fibroblasts. In clinical trials, VEGF inhibitors will reduce connective tissue symptoms (joint pain, hypermobility-related dysfunction) more than systemic fatigue symptoms.
Limitations. Moschini 2026 is a murine tendinopathy model; human data are limited. Tendons are specialized tissues; whether the HIF-1alpha-VEGF-MMP-3 cascade operates identically in muscle or vascular connective tissue is unknown. VEGF inhibitors have significant toxicity (hypertension, proteinuria, thrombosis risk) that may limit their use in ME/CFS. The hypothesis predicts tissue-specific pathology (tendons most affected) while ME/CFS is systemic.
Certainty: 0.30. Gut dysbiosis produces bacterial proteases that degrade connective tissue locally (intestinal wall) and systemically, contributing to connective tissue pathology and autoantibody generation against collagen/elastin in ME/CFS. This microbiome-ECM axis bridges the gut-immune interface (Chapter Gastrointestinal and Microbiome Dysfunction) to systemic connective tissue pathology. (Wirth 2026)
Mechanism. The gut microbiome produces proteases as part of normal metabolism, but dysbiotic states are characterized by altered protease profiles—increased elastase, collagenase, and gelatinase-producing bacteria. These proteases can: (1) degrade intestinal wall collagen and elastin, increasing gut permeability (“leaky gut”); (2) enter systemic circulation via the compromised barrier; (3) degrade extracellular matrix throughout the body, particularly in vascular walls where they access connective tissue; (4) release ECM fragments that act as neoantigens, triggering autoantibody production. This creates a self-reinforcing cycle: dysbiosis → protease production → gut barrier breakdown → systemic protease spread → connective tissue degradation → immune activation → further dysbiosis.
Evidence from other conditions. In inflammatory bowel disease, bacterial proteases contribute to tissue damage and fistula formation. In systemic sclerosis, altered gut microbiome and increased bacterial protease activity correlate with fibrosis. In ME/CFS, gut dysbiosis is well-documented (Chapter Gastrointestinal and Microbiome Dysfunction), and connective tissue pathology is clinically apparent (hypermobility, skin hyperextensibility). The missing link—whether dysbiosis-derived proteases mediate this connection—has not been tested.
Testing the protease hypothesis. Direct experimental approaches include: (1) measuring serum protease activity with bacterial origin signatures (mass spectrometry proteomics comparing ME/CFS vs. control serum); (2) identifying protease-producing bacteria in ME/CFS stool samples (metagenomic screening for elastase, collagenase, gelatinase genes); (3) testing whether ME/CFS serum degrades collagen/elastin matrices in vitro more than control serum; (4) determining whether protease inhibitors (e.g., doxycycline at subantimicrobial MMP-inhibitory doses) reduce connective tissue symptoms in ME/CFS.
Falsifiable prediction. ME/CFS patients will show: (1) elevated serum protease activity with bacterial signatures; (2) increased abundance of protease-producing bacterial species in stool; (3) serum ECM degradation products (CTX, NTx, elastin fragments) correlating with both gut permeability markers (zonulin) and protease activity; (4) doxycycline (20 mg BID, subantimicrobial MMP-inhibitory dose) reducing both serum protease activity and connective tissue symptoms.
Limitations. This is a novel, speculative connection with no direct ME/CFS data. Distinguishing bacterial proteases from host MMPs in circulation is technically challenging. Not all ME/CFS patients have documented gut dysbiosis; the hypothesis predicts subgroup specificity. Antibiotics or protease inhibitors may disrupt the microbiome in unpredictable ways.
5 Fibronectin–IgG Immune Complexes and Homeostatic Antibody Depletion
Certainty: 0.38. Prusty et al. identified directionally discordant fibronectin (Fn1) biology in ME/CFS — increased circulating Fn1 in serum yet depletion of Fn1 in IgG-bound circulating immune complexes (CICs). (Watton and Prusty 2026)
This pattern argues against a simple “more fibronectin everywhere” phenomenon and instead supports selective alteration in immune-complex composition and handling. Fibronectin is not merely a structural extracellular matrix protein; it participates in innate immune signaling and opsonization-like functions through binding to complement components (C1q, C3) and can modulate inflammatory responses through TLR4 engagement and mast cell/platelet activation. The depletion of Fn1 from CICs could plausibly imply impaired pathogen clearance and impaired scavenging of cellular debris, which would increase downstream immune activation pressure and diversify autoreactivity over time. (Watton and Prusty 2026)
Homeostatic antibody loss. Complementing the Fn1-IgG findings, natural IgM antibodies against fibronectin — which have homeostatic scavenger/protector/regulator roles — were observed to be depleted after COVID infection. This strengthens the argument that immune perturbation in post-infectious syndromes involves not only pathogenic antibodies but also the loss of protective, homeostatic antibody functions that normally constrain inflammation and facilitate immune-complex processing. (Watton and Prusty 2026)
Functional significance. Patient-derived IgG enters endothelial cells (HUVECs) and, in a subset of patients with a sex-stratified signal, drives mitochondrial network fragmentation and measurable changes in mitochondrial proteins and energetics. Passive transfer of ME/CFS IgG to healthy PBMCs induced secretion of specific inflammatory cytokines (with IL-1\(\beta\) reaching statistical significance across the cohort), demonstrating that circulating immunoglobulin fractions can act as functional effectors rather than simply passive biomarkers. (Watton and Prusty 2026)
Taken together, these findings support a model in which ME/CFS and post-acute infectious syndromes involve: (a) altered immune-complex composition and homeostatic antibody depletion, plus (b) immunoglobulin-mediated perturbation of endothelial mitochondrial resilience. This mechanistic bridge directly connects systemic immune dysregulation to the endothelial and mitochondrial vulnerability described in Chapters Energy Metabolism and Mitochondrial Function and Cardiovascular Dysfunction. (Certainty: 0.38)
Falsifiable predictions:
- Restoring Fn1 content in IgG-bound CICs (via exogenous Fn1 supplementation or blocking IgG-Fn1 binding) will normalise endothelial cell responses to oxidative stress (improved barrier integrity, preserved mitochondrial respiration)
- ME/CFS patients with the most severe Fn1 depletion in CICs will show correspondingly greater endothelial dysfunction on provocative testing
- Natural IgM anti-fibronectin levels will correlate inversely with disease severity in post-infectious ME/CFS
6 Abortive Viral Reactivation as a Common Post-Infectious Mechanism
A pivotal conceptual advance has been the recognition that abortive or incomplete viral reactivation — characterized by restricted expression of immunostimulatory viral proteins without production of infectious virions — may represent a common mechanism across multiple persistent or latent viruses (Watton and Prusty 2026). In such states, viral genomes are transcriptionally active enough to generate proteins (e.g., herpesvirus dUTPases (Hennig et al. 2022)) capable of engaging innate immune sensors, yet insufficiently active to trigger classical cytopathic effects or detectable viraemia.
This model resolves longstanding inconsistencies between strong epidemiological links to herpesviruses and repeated failure to demonstrate active replication. It represents a departure from traditional infection models rooted in Koch’s postulates, which assume that pathogenicity requires replicating organisms and tissue invasion. In post-infectious syndromes such as ME/CFS, pathophysiology may involve persistent or intermittently renewed immune engagement with viral-derived products, generated episodically or at low levels, sufficient to maintain danger signaling but insufficient to provoke sterilising immunity or straightforward diagnostic detection. (Watton and Prusty 2026) (Certainty: 0.55)
While herpesviruses have provided the most experimentally tractable model for abortive reactivation (HHV-6 miR-aU14; EBV dUTPase), the conceptual implications extend beyond a single viral family. Does abortive reactivation also occur with enteroviruses, SARS-CoV-2, or other persistent viruses implicated in ME/CFS? Identifying shared molecular signatures of abortive reactivation — such as restricted viral protein expression patterns, specific innate immune sensor engagement, or EV cargo signatures — could provide diagnostic markers and therapeutic targets applicable across post-infectious conditions regardless of the initial trigger. (Watton and Prusty 2026)
7 Speculative Immune-Targeted Interventions
Certainty: 0.35. Probability of clinically meaningful efficacy in ME/CFS: 0.05. If ATG13 is a circulating DAMP amplifying CDR downstream of abortive viral reactivation, neutralising monoclonal antibodies could reduce inflammatory signaling. This is analogous to anti-cytokine biologics but targets a novel DAMP pathway. ATG13 mAbs would require development from scratch (no existing therapeutic pipeline). The therapeutic concept is mechanistically coherent but requires ATG13 to be a causal driver rather than an epiphenomenon. Falsifiable: anti-ATG13 mAb treatment in ex vivo ME/CFS PBMC cultures will reduce IL-1\(\beta\), TNF-\(\alpha\), IL-6 and shift mitochondrial morphology toward interconnected networks.
Certainty: 0.45. Probability of clinically meaningful efficacy in ME/CFS: 0.10. TRPM3 calcium channel dysfunction in NK cells is a reproducible ME/CFS finding. TRPM3 agonists (pregnanolone sulfate, CIM0216) could restore calcium flux, normalising mitochondrial function, redox regulation, and endothelial responsiveness — all calcium-dependent processes. Pregnanolone sulfate is an endogenous neurosteroid with established safety profile; CIM0216 is a research tool. No ME/CFS TRPM3 agonist trial exists. Falsifiable: TRPM3 agonist treatment will restore calcium influx kinetics, improve mitochondrial membrane potential, increase NK cytotoxicity, and reduce ROS in ME/CFS cells.
Certainty: 0.42. Probability of clinically meaningful efficacy in ME/CFS: 0.06. SMPDL3B-mediated lipid raft disorganization may underlie receptor mis-localization (TRPM3, \(\beta\)-adrenergic). Sphingolipid modulators (myriocin, FTY720/fingolimod, sphingosine kinase inhibitors) could normalise raft fluidity and restore signal transduction. FTY720 is FDA-approved for multiple sclerosis — a cross-disease precedent for sphingolipid modulation. However, FTY720 induces lymphopenia (lymphocyte sequestration), which could be counterproductive in an already immune-compromised condition. Falsifiable: sphingolipid modulator treatment will normalise lipid raft fluidity (Laurdan staining), restore TRPM3/\(\beta\)-adrenergic receptor surface localization, and improve cAMP/calcium signaling.
Certainty: 0.38. Probability of clinically meaningful efficacy in ME/CFS: 0.04. SMPDL3B is an acid sphingomyelinase (ASM)-like protein. ASM inhibitors (amitriptyline, desipramine — functional inhibitors of ASM) are already prescribed to ME/CFS patients for pain/sleep, providing a serendipitous existing-use cohort. If amitriptyline’s benefit in ME/CFS is partly mediated through ASM inhibition and lipid raft normalization rather than NMDA antagonism alone, this would explain the efficacy at low doses where antidepressant effects are absent. Falsifiable: ASM modulators will normalise SMPDL3B activity in ME/CFS immune cells, restore lipid raft fluidity, and improve TRPM3 function.
Certainty: 0.35. Probability of clinical diagnostic utility: 0.05. Directionally discordant Fn1 biology may reflect broader immunological memory dysfunction. IgG-mediated pathogen clearance and cellular debris scavenging are compromised, creating feedback where new triggers exacerbate unresolved debris accumulation. Reduced natural IgM anti-fibronectin antibodies (documented after COVID) represent loss of homeostatic protection. Falsifiable: ME/CFS patients will show impaired clearance of labeled immune complexes in vitro, reduced IgM repertoire diversity (NGS), and exaggerated inflammatory responses to immune complex rechallenge.
Certainty: 0.30. Probability of clinical relevance: 0.02. ME/CFS shows ~3:1 female predominance. SMPDL3B regulation may be estrogen-responsive, providing a mechanistic substrate for sex differences in lipid raft organization and clinical presentation. This is entirely speculative — SMPDL3B sex-specificity has not been studied in any condition. Falsifiable: SMPDL3B expression will correlate with estrogen levels across menstrual cycle phases and differ between males and females with matched ME/CFS severity.
Certainty: 0.35. Chronic \(\beta_2\)-AAb exposure may trigger receptor desensitization followed by compensatory \(\beta_2\)-AR upregulation on immune cells (monocytes, NK cells) and endothelial cells, paradoxically increasing catecholamine sensitivity. This “rebound hypersensitivity” could contribute to PEM after minor sympathetic surges. (Azcue et al. 2026) (Hackel et al. 2025). Prediction: \(\beta_2\)-AR density (radioligand binding or PET) inversely correlated with \(\beta_2\)-AAb titers at rest but positively correlated with post-exertional symptom severity. Ex vivo monocytes from \(\beta_2\)-AAb-positive patients show amplified cytokine response to isoproterenol vs \(\beta_2\)-AAb-negative. Immunoadsorption normalizes \(\beta_2\)-AR density within 2 weeks. Limitation: receptor density never measured in ME/CFS. Falsifiable by radioligand binding in \(\beta_2\)-AAb-positive vs negative PBMCs.
Certainty: 0.32. M3 mAChRs on vagal afferents in nucleus tractus solitarius may be desensitized by chronic low-level M3-AAb agonism, creating a “vagal blind spot” where peripheral inflammatory/metabolic signals fail to trigger parasympathetic compensation. After exertion, unopposed sympathetic activation persists → PEM. PCC borderline/pathological M3 results (Azcue et al. 2026) may indicate acute-phase vagal damage with M3-AAb overlay. Prediction: M3-AAb-positive patients show reduced compensatory parasympathetic response after isometric handgrip vs M3-AAb-negative. Baroreflex sensitivity improves after M3-AAb immunoadsorption within 3 weeks. Limitation: vagal afferent receptor expression not measured in ME/CFS; M3-AAb functional status undetermined. Falsifiable by baroreflex sensitivity comparison stratified by M3-AAb titers pre/post immunoadsorption.
Certainty: 0.25. Estrogen upregulates \(\beta_2\)-AR on B cells (ER\(\alpha\) binding to \(\beta_2\)-AR promoter), increasing antigenic target density. BAFF-mediated B cell survival further preserves \(\beta_2\)-AAb-producing clones in females. This may partially explain 4:1 female predominance in ME/CFS. PCC sex ratio closer to 1:1 because acute COVID-19 B cell depletion resets epitope repertoire. Prediction: \(\beta_2\)-AAb titers correlate with serum estrogen across menstrual cycle phases; male ME/CFS patients show lower \(\beta_2\)-AAb titers vs females matched for severity; \(\beta_2\)-AR expression on B cells (flow cytometry) higher in female ME/CFS vs male vs HC. Limitation: no direct evidence linking estrogen to GPCR AAb titers in ME/CFS; single cross-disease inference chain. (Azcue et al. 2026).
The GPCR autoantibody content in this paper identifies beta2-adrenergic and muscarinic receptor autoantibodies as a promising mechanistic axis supported by multiple independent groups (Loebel, Bynke, Sotzny, Azcue, Wallukat, Stein), early therapeutic signals (immunoadsorption, daratumumab), and convergent cross-disease evidence (CRPS, FM passive transfer). However, the framework rests on a contested measurement platform (CellTrend ELISA) whose specificity has been challenged: Vernino 2022 found 98.3% POTS positivity and 100% control positivity using the same methodology; Germain 2025 (n=172, REAP+Luminex, 7,542 interactions) found complete null results for GPCR autoantibodies in ME/CFS. The strongest quantitative correlation (Azcue2026: beta2-AAb vs sympathovagal imbalance, r=0.45, r^2=0.20) explains only 20% of HRV variance. No clinical GPCR autoantibody test is available in routine care. The treatment protocols, biomarker proposals, and mathematical models downstream of this section represent provisional scaffolding for hypothesis testing — not validated clinical pathways. The simplest explanation for the CellTrend vs REAP discrepancy (non-specific ELISA binding) would nullify most of the GPCR-AAb-specific proposals. Readers should regard these as a research agenda, not as established mechanism.